$Brentuximab vedotin for treatment of relapsed or refractory malignant lymphoma: results of a systematic review and meta-analysis of prospective studies$

Brentuximab vedotin for treatment of relapsed or refractory malignant lymphoma: results of a systematic review and meta-analysis of prospective studies

Runzhe Chen, Fei Wang, Hongming Zhang, Baoan ChenDepartment of Hematology and Oncology (Key Department of Jiangsu Medicine), Zhongda Hospital, Medical School, Southeast University, Nanjing, Jiangsu Province, People’s Republic of ChinaBackground: Recently, brentuximab vedotin has b...

Full description

Bibliographic Details
Main Authors:	Chen R, Wang F, Zhang H, Chen B
Format:	Article
Language:	English
Published:	Dove Medical Press 2015-04-01
Series:	Drug Design, Development and Therapy
Online Access:	http://www.dovepress.com/brentuximab-vedotin-for-treatment-of-relapsed-or-refractory-malignant--peer-reviewed-article-DDDT

Similar Items

Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma
by: Chen R, et al.
Published: (2015-03-01)

Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma
by: Siddiqi T, et al.
Published: (2014-02-01)

Brentuximab vedotin in the treatment of relapsed and refractory forms of Hodgkin lymphoma
by: E A Demina
Published: (2016-06-01)

Brentuximab Vedotin: New Possibilities for Treatment of Relapses and Refractory Hodgkin’s Lymphomas
by: EA Demina
Published: (2015-10-01)

The Use of Brentuximab Vedotin in Relapsed/Refractory Hodgkin’s Lymphoma in the Kransnodar Region
by: OD Serdyuk, et al.
Published: (2018-01-01)

Emerging Pharmacotherapy for Relapsed or Refractory Hodgkins Lymphoma: Focus on Brentuximab Vedotin
by: Michelle Furtado, et al.
Published: (2012-01-01)

Emerging Pharmacotherapy for Relapsed or Refractory Hodgkin's Lymphoma: Focus on Brentuximab Vedotin
by: Michelle Furtado, et al.
Published: (2012-01-01)

Profile of brentuximab vedotin and its potential in the treatment of relapsed or refractory Hodgkin lymphoma
by: Illidge T, et al.
Published: (2012-05-01)

Brentuximab Vedotin Treatment for Primary Refractory Hodgkin Lymphoma
by: Hung-Bo Wu, et al.
Published: (2013-01-01)

Durability Results of Treatment with Brentuximab Vedotin in Combination with Nivolumab in Patient with Relapsed or Refractory Hodgkin Lymphoma
by: Minhas, Ahmed, et al.
Published: (2020)

TARGETED THERAPY WITH BRENTUXIMAB VEDOTIN IN RELAPSED AND REFRACTORY FORMS OF CLASSICAL HODGKIN LYMPHOMA
by: E. A. Demina
Published: (2017-11-01)

COST-EFFECTIVENESS ANALYSIS OF BRENTUXIMAB VEDOTIN IN ADULTS WITH RELAPSED OR REFRACTORY HODGKIN’S LYMPHOMA
by: G. R. Khachatryan, et al.
Published: (2016-04-01)

Brentuximab vedotin as a salvage treatment for relapsed and refractory Hodgkin lymphoma patients in Taiwan
by: Feng-Ming Tien, et al.
Published: (2019-10-01)

Potentials of brentuximab vedotin in the treatment of relapse/refractory cutaneous T-cell lymphomas: literature review and authors’ observation
by: L. G. Gorenkova, et al.
Published: (2019-07-01)

A Cost-effectiveness Analysis of Brentuximab Vedotin in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
by: Margaret Hux, et al.

Brentuximab vedotin for relapsed or refractory CD30+ Hodgkin lymphoma: a multicenter analysis from Asia
by: Yang QM, et al.
Published: (2014-09-01)

Brentuximab Vedotin for Treatment of Non-Hodgkin Lymphomas: A Systematic Review
by: Berger, Garrett, et al.
Published: (2017)

Pharmacoeconomic analysis of therapy with brentuximab vedotin, nivolumab and pembrolizumab in patients with relapsed Hodgkin’s lymphoma
by: N. A. Avxentyev, et al.
Published: (2020-12-01)

Real experience of brentuximab vedotin for cutaneous T cell lymphomas
by: F. Keklik Karadag, et al.
Published: (2020-10-01)

The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma
by: Lai C, et al.
Published: (2019-12-01)

Brentuximab vedotin is the first target drug in the treatment of hodgkin lymphoma
by: G. S. Tumyan
Published: (2018-11-01)

Safety and Efficacy of Brentuximab Vedotin in the Treatment of Classic Hodgkin Lymphoma
by: Makita S, et al.
Published: (2020-06-01)

Treatment patterns and costs of care for patients with relapsed and refractory Hodgkin lymphoma treated with brentuximab vedotin in the United States: A retrospective cohort study.
by: Shelagh M Szabo, et al.
Published: (2017-01-01)

Successful Treatment of a Patient with Brentuximab Vedotin-Refractory ALK-Negative Anaplastic Large Cell Lymphoma with Romidepsin
by: Tatsuro Jo, et al.
Published: (2020-11-01)

Patient-reported outcomes of brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma
by: Chen R, et al.
Published: (2016-04-01)

Fatal pancreatitis occurred in a patient with refractory CD30+ anaplastic large cell lymphoma after brentuximab vedotin treatment
by: Chi-Ching Chen, et al.
Published: (2017-03-01)

Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin
by: Chen X, et al.
Published: (2013-12-01)

Brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma: an evidence-based review
by: Donato EM, et al.
Published: (2018-08-01)

Successful brentuximab vedotin monotherapy against late relapse of classical Hodgkin lymphoma 6 years after first remission
by: Kana Nagashima, et al.
Published: (2020-03-01)

Successful salvage therapy for refractory primary cutaneous gamma-delta T-cell lymphoma with a combination of brentuximab vedotin and gemcitabine
by: Sophie Voruz, et al.
Published: (2021-05-01)

Use of Brentuximab Vedotin in a Non-HIV Patient with Primary Effusion Lymphoma
by: Joana Ferra, et al.
Published: (2021-02-01)

Brentuximab vedotin for refractory anaplastic lymphoma kinase-negative anaplastic large cell lymphoma in leukemic phase with <em>RUNX3</em> overexpression
by: Yusuke Yamashita, et al.
Published: (2020-05-01)

Combination therapy with brentuximab vedotin and cisplatin/cytarabine in a patient with primarily refractory anaplastic lymphoma kinase positive anaplastic large cell lymphoma
by: Heidegger S, et al.
Published: (2014-06-01)

Brentuximab vedotin (Adcetris®) in therapy of system anaplastic large cell lymphoma. Case report
by: A. A. Semenova, et al.
Published: (2019-01-01)

Cost-effectiveness of brentuximab vedotin in advanced stage Hodgkin’s lymphoma: a probabilistic analysis
by: A. J. N. Raymakers, et al.
Published: (2020-10-01)

SUCCESSFUL USE OF BRENTUXIMAB VEDOTIN IN THE TREATMENT OF PROGRESSIVE PERIPHERAL UNSPECIFIED T-CELL LYMPHOMA IN AN ELDERLY FEMALE PATIENT
by: L. G. Gorenkova, et al.
Published: (2017-06-01)

PHARMACOECONOMIC ANALYSIS OF BRENTUXIMAB VEDOTIN THERAPY IN RELAPSED OR REFRACTORY CD30+ SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA IN PATIENTS OVER 18 YEARS OF AGE: HEALTH BUDGET IMPACT ANALYSIS
by: A. S. Kolbin, et al.
Published: (2017-05-01)

Primary Cutaneous Anaplastic Large Cell Lymphoma of the Oral Cavity Successfully Treated with Brentuximab Vedotin
by: Federico Meconi, et al.
Published: (2019-01-01)

Assessment of the efficiency of Brentuximab Vedotin in patients with pulmonary Hodgkin Lymphoma by the mean of neutrophil to lymphocyte ratio
by: Gokhan Erdem, et al.
Published: (2018-04-01)

Increased Efficacy of Brentuximab Vedotin (SGN-35) in Combination with Cytokine-Induced Killer Cells in Lymphoma
by: Laura Esser, et al.
Published: (2016-07-01)

Cannot write session to /tmp/vufind_sessions/sess_7ct5g2r13btpe70t1t00grlnhj